Skip to main content
Advertisement
Advertisement
AQST
AQST logo
Aquestive Therapeutics, Inc. Common Stock
3.46
USD
Sponsored
-0.25
-6.61%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

3.51

+0.05
+1.45%

Aquestive Therapeutics, Inc. Common Stock (AQST) Earnings

AQST Earnings Reports

Positive Surprise Ratio

AQST beat 17 of 34 last estimates.

50%

Next Report

Date of Next Report
Mar 02, 2027
Estimate for Q4 26 (Revenue/ EPS)
$13.97M
/
-$0.11
Implied change from Q3 26 (Revenue/ EPS)
+84.84%
/
-15.38%
Implied change from Q4 25 (Revenue/ EPS)
+7.32%
/
-26.67%

Aquestive Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 03, 2026, AQST reported earnings of -0.13 USD per share (EPS) for Q3 26, missing the estimate of -0.11 USD, resulting in a -10.17% surprise. Revenue reached 7.56 million, compared to an expected 11.24 million, with a -32.75% difference. The market reacted with a -2.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.11 USD, with revenue projected to reach 13.97 million USD, implying an decrease of -15.38% EPS, and increase of 84.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Aquestive Therapeutics, Inc. Common Stock reported EPS of -$0.13, missing estimates by -10.17%, and revenue of $7.56M, -32.75% below expectations.
The stock price moved down -2.06%, changed from $3.88 before the earnings release to $3.80 the day after.
The next earning report is scheduled for Mar 02, 2027.
Based on -- analysts, Aquestive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $13.97M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement